StemCell Therapy

Hearing loss and tinnitus can occur due to noise exposure and may be associated with adverse effects on overall well-being due to anxiety, depression, sleep disorders, and various comorbidities.1 Determining the exact cause, circumstances of onset, and contributing factors to hearing loss and/or tinnitus can be challenging. In some cases, hearing loss can be attributed to a singular medical cause such as a disease, genetic condition, autoimmune disorder, medical treatment, or head trauma. However, in many individuals who are diagnosed with bilateral sensorineural hearing loss, the root cause may be difficult to determine, especially when considering a lifetime of exposures to noise and other ototoxicants. Evidence from animal research suggests that noise exposure may result in delayed-onset auditory system damage, which means that traditional audiometric testing may not immediately reveal noise-related auditory damage.2 Additionally, tinnitus is an entirely subjective experience that cannot be measured directly, and time-consuming psychoacoustic testing for tinnitus is not feasible in many clinical situations.3 Lastly, it can be difficult to accurately and precisely assess how hearing loss and tinnitus may have impacted a patient's quality of life; such an assessment relies on subjective patient reports usually gathered in conversations during a clinical appointment.

Shutterstock/wavebreakmedia, audiology, noise, military.

As audiology clinicians, our responsibility includes educating patients about factors that may contribute to hearing loss, helping them understand what may have caused the loss, mitigating hearing loss progression to the extent possible, and developing plans for future management of hearing loss and/or tinnitus. However, clinical appointments do not always allow adequate time for thorough and accurate case history review. With limited information derived from a case history and audiologic assessment, it may be difficult to determine the cause, onset, and risk for progression of auditory decline. To accurately understand an individual's hearing history as it relates to noise exposure, detailed information is needed about types, extent, and frequency of exposures throughout the patient's life. It is challenging but important to consider the fullest possible range of potential noise exposure, such as musical concerts, sporting events, fireworks, lawn equipment, noisy restaurants and bars, firearms, and motorsports. Assessment is all the more difficult because there is no widely accepted and meaningful way to interpret and quantify all relevant exposures. Audiologists must primarily hypothesize how a patient's noise exposure history may contribute to the eventual onset of hearing loss and/or tinnitus, and exercise best clinical judgment based on experience to project future outcomes. Audiologists use Occupational Safety and Health Administration (OSHA) and National Institute for Occupational Safety and Health (NIOSH) exposure guidelines to counsel patients on the proper use of hearing protection to prevent auditory damage, but have few options when counseling to explain hearing damage that may have already occurred.

Epidemiologic research is needed to better understand longitudinal relationships between noise exposure, hearing loss, and tinnitus.4 To address these relationships, the Noise Outcomes in Service Members Epidemiology Study (NOISE Study) was developed as a joint effort by the Department of Veterans Affairs (VA) Rehabilitation Research & Development (RR&D) National Center for Rehabilitative and Auditory Research (NCRAR) in Portland, OR, and the Department of Defense (DoD) Hearing Center of Excellence (HCE) in San Antonio, TX.5 This article explains the importance of longitudinal epidemiologic research as it relates to hearing health care, describes the data collection methods of the ongoing NOISE Study, and discusses how some NOISE Study tools can be used in clinical practice to improve patient outcomes.

Active duty military service members and veterans may be more susceptible than the general public to hearing loss and tinnitus, likely due to risk factors associated with military service, including noise exposure, chemical and blast exposures, and traumatic brain injury (TBI).6 In 2018, tinnitus and hearing loss were the two most prevalent military service-connected disabilities, with over two million cases.7

In 2006, the Institute of Medicine (IOM) acted on a congressional mandate to address issues related to hearing loss and tinnitus in the military. The IOM published Noise and Military Service: Implications for Hearing Loss and Tinnitus, which encouraged researchers to collect longitudinal data from service members and veterans relating to military and nonmilitary risk factors, auditory function, presence and severity of tinnitus, and other potentially correlated variables.8 The objectives of the IOM's recommendations were to learn more about the onset of hearing loss and tinnitus and how they change over time. This type of research would help to identify cohorts at greatest risk for auditory injury, guide effective hearing conservation programs, inform the development of advanced treatments to mitigate the underlying causes of hearing loss, and determine whether delayed-onset hearing loss and/or tinnitus occurs in humans. The NOISE Study was initiated as a direct result of the IOM's recommendations.

The NOISE Study, which began recruitment in 2014, aims to determine the prevalence, etiology, and effects of early-onset tinnitus and hearing loss among military service members in active duty and those who have recently left (within the past two and a half years ).5 Ultimately, this will involve a cohort of at least 1,500 participants and longitudinal annual follow-up data. Data collected for the study include noise and ototoxicant exposures, audiometric measurements, pre-existing medical conditions, including a history of TBI and mental health conditions, and perceived effects on quality of life. Recently, separated service members are being recruited to participate in the NOISE Study at the NCRAR, and active duty service members are being recruited at the HCE. To date, over 1,000 participants have been enrolled.

Longitudinal and epidemiologic studies lend themselves to collecting an abundance of data. The NOISE Study captures comprehensive audiometric measures gathered through pure-tone air conduction (0.25-16 kHz) and bone conduction (0.5-4 kHz) audiometry, immittance testing (tympanometry and acoustic reflexes), speech audiometry (speech reception thresholds and word recognition), Speech Recognition in Noise Testing (SPRINT), dichotic digits testing, distortion product otoacoustic emissions (DPOAE), and, when applicable, tinnitus loudness match, pitch match, and maskability testing (minimum masking level). This thorough audiometric evaluation takes approximately 90-120 minutes conducted first at the time of enrollment and then repeated every five years.

The NOISE Study also administers multiple questionnaires (15 for all participants, 18 for those with tinnitus) upon enrollment into the study, prior to audiometric evaluation, and again annually over the life of the study. In the first five years of the study, questionnaires were administered as paper forms in packets of up to 70 single-sided pages. Many participants found it cumbersome to manage and return the bulky questionnaire packets every year. This led to frequent data collection and processing lags and the need for time-consuming reminder phone calls and e-mails. In late 2019, all NOISE Study questionnaires were converted to an electronic format and made accessible via a web-based, HIPAA-compliant data collection tool (Research Electronic Data Capture or REDCap).9,10 While the use of this platform is still relatively new to the NOISE Study, we have already seen faster and higher rates of return on the annual follow-up questionnaires and observed fewer data error incidents.

The NOISE Study's successful transition to an electronic data collection platform highlights the potential value of automated data collection for clinical purposes. Clinical appointment time is frequently limited, forcing clinicians to prioritize and manage their time carefully and to consider what can be done to make clinical encounters as effective and beneficial as possible for patients. While it is not possible to administer all available instruments and outcome measures that might be informative, some of the NOISE study questionnaires could be implemented practically in clinical settings. Instead of asking patients to spend an additional 60 minutes in the medical office to fill out questionnaires, they could be given the option to complete the questionnaires electronically at their convenience before or after their appointment and from the comfort of their own home. This may help clinicians develop a more comprehensive understanding of their patients, and, in turn, give patients more confidence in the thoroughness of their care and treatment plan. The following questionnaires used in the NOISE Study could be of interest to practicing clinicians.

Tinnitus Screener (TS). This six-item tool was designed to determine the presence of tinnitus and to categorize identified tinnitus as constant, intermittent, occasional, or temporary.11 It also determines whether tinnitus is acute (more than six months) or chronic (less than six months). The TS takes only two to three minutes to complete, and can be included as an initial tool if a patient has specific questions about tinnitus, part of a routine case history, or administered before or after audiologic assessment. It can be a helpful starting point for counseling to determine whether intervention for tinnitus may be necessary.

Tinnitus and Hearing Survey (THS). When determining the need for clinical intervention, it is essential to distinguish between tinnitus and hearing difficulties.12 The THS is a 10-item instrument that can be used to distinguish problems due to tinnitus from those due to hearing loss or decreased sound tolerance (hyperacusis).13 Patients often describe their hearing difficulties as tinnitus, or vice versa. For these cases, the THS, which was designed to assess subjective distress related to a specific issue, can be used to examine hearing and tinnitus complaints separately. Two survey items address hyperacusis since this is often reported by patients who have tinnitus.

Many patients with hearing loss are hesitant to proceed with hearing aids. They may be unaware that tinnitus and hearing loss can be related, so they don't consider amplification to be potentially therapeutic for tinnitus. The THS may help in developing a better understanding of the source of a patient's auditory complaints.

Lifetime Exposure to Noise and Solvents Questionnaire (LENS-Q). This is an in-depth, self-report questionnaire used to quantify a lifetime history of continuous and impulse noise exposures as well as exposure to potentially ototoxic chemicals/-solvents from military occupational, non-military occupational, and non-occupational/recreational sources.14 Respondents are asked yes or no exposure questions in each section. Those who answer yes are asked to provide information concerning exposure duration, frequency, and use of hearing protection or other safety equipment. These details are essential to the longitudinal epidemiologic identification of potential risk factors for hearing loss and tinnitus.

Although the LENS-Q is not yet available for clinical use because the normative data have not yet been published, this instrument could eventually provide a basis for standardized scoring that describes an individual's risk level for hearing loss due to noise or chemical exposures. On average, the questionnaire takes 30 minutes to complete. If made available for completion prior to an audiologic clinical appointment, its findings could be very helpful as a framework for counseling.

Determining the onset and cause of hearing loss can be difficult, especially for patients who present with a lengthy history of noise and/or solvent exposure. No universally accepted method exists to identify individuals who are at increased risk for hearing loss based on exposure history, and no tool can effectively predict the impact of noise exposure on auditory function later in life. The ongoing NOISE Study aims to evaluate such effects in military service members and veterans. Tools and methods that have been created and/or implemented for the NOISE Study can also benefit patient outcomes in the audiology clinic setting. These tools can be adapted to obtain standardized measures and provide helpful perspectives to guide management plans.

Editor's note: The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. W81XWH-17-1-0020. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The use of REDCap acknowledges support from grant No. UL1TR002369.

Originally posted here:
NOISE Study: Examining Hearing Loss, Tinnitus in the U.S.... : The Hearing Journal - LWW Journals

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read more:
Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,...

The National Institutes of Health (NIH) has announced it will provide $75 million to continue funding its Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Networkwith a new emphasis on expanding genetic diversity within its studies.

NIHs National Human Genome Research Institutes (NHGRI) first launched the eMERGE Network in 2007 to use electronic health records and large biorepositories for genomics research that could be applied to clinical care. Now, more recent research has highlighted the need to generate datasets from more diverse populations to better understand estimates of disease risk in the general population, according to Prabarna Ganguly, Ph.D., science writer and editor for NHGRI, in a July 1 announcement.

The funding will begin this year and continue over the next five years, Ganguly said, with $61 million going directly to four clinical sites, including the Mayo Clinic, Vanderbilt University Medical Center, Brigham and Womens Hospital and Northwestern University. NIH plans for these sites to collectively recruit some 10,000 patientswith 35 percent to come from diverse populations.

In addition, NIH will fund six new enhanced diversity clinical sites, to include: the University of Alabama, the Icahn School of Medicine at Mount Sinai, Cincinnati Childrens Hospital Medical Center, Columbia University, the Childrens Hospital of Philadelphia, and the University of Washington Medical Center. These sites will recruit about 15,000 patients, with 75 percent or more coming from diverse ancestries, Ganguly said.

The goal of the clinical sites is to recruit participants from diverse groups, such as racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes, Ganguly said. The sites will then conduct and validate genomic risk-assessment and management methods for a number of common diseases, including coronary heart disease, Alzheimers disease, and diabetes.

The need for expanding the diversity of NIHs genetic pool for research is driven by the lack of diversity in polygenic risk scores, a new approach for assessing disease risk based on DNA variants. Until recently, these scores have almost exclusively involved people of European ancestry, Ganguly said. It is not clear how well the findings from these initial studies can be used for risk assessment in non-European ancestry populations.

NIH will also focus on adding new research variables such as age, body-mass index, alcohol use and other clinical dataall of which can affect risks for contracting diseases, Ganguly said.

The newly funded eMERGE sites will also leverage the NHGRI Genomic Data Science Analysis, Visualization, Informatics Lab-space (AnVIL) cloud-based resource to develop tools and workflows for generating integrated risk scores to be shared with the biomedical research and clinical genomics communities, Ganguly said. In addition, the agency will inform clinical decision support platforms with the data it collects from the eMERGE electronic health records.

NIH has allotted $13.4 million of the funding to go to Vanderbilt University for an eMERGE Network coordinating center.

Read more here:
NIH to Provide $75M to Increase Diversity in Its eMERGE Network - Clinical OMICs News

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

See the rest here:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Several new genes linked to an exceptionally long life have been discovered, according to a new study that examined the genomes of people living into their 100s, known as centenarians.

Using a new method, the researchers found four genes linked with a very long life: A gene called ABO, which is involved in determining blood type; a gene called CDKN2B, which regulates cell division; a gene called APOE, which is linked with Alzheimer's disease; and a gene called SH2B3, which was previously found to extend life in fruit flies.

The researchers hope that future studies will uncover even more genes linked with longevity, and figure out how these genes may affect the aging process.

"There's a reasonably strong genetic component to becoming a centenarian, and we want to find out what that is," said study researcher Stuart Kim, a professor in the Department of Developmental Biology and Genetics at Sanford University. "We're beginning to unravel the mystery" of why some people age so successfully compared to the normal population, Kim said. [Extending Life: 7 Ways to Live Past 100]

Previous studies have attempted to find variations in genes that are more common in the very old compared with younger people, but haven't had much luck. These studies looked through millions of variations in the human genome, but they might have missed some important associations.

The new study aimed to narrow the search for genes linked with long life by focusing on ones that are known to strongly affect a person's risk of age-related disease, like heart disease and Alzheimer's. The thinking is that these diseases increase a person's risk of dying early, and so genetic variants that increase the risk of these diseases would also decrease the chances of a long life, the researchers said.

The researchers first searched for longevity-linked genes in a population of about 800 people over age 100 and 5,400 people over age 90.

They found eight genes that were linked with a long life span, and were able to confirm four of these genes in a follow-up analysis of about 1,000 people ages 100 or over.

The study found that certain variants in the ABO, CDKN2B, APOE and SH2B3 genes were more common in centenarians than in people with a typical life span. (Adults in the United States have an average life expectancy of about 79 years, according to the Centers for Disease Control and Prevention.)

For example, the study found that the a genetic variation associated with type O blood was more common in centenarians than in the study's control group, meaning that there were slightly more centenarians with type O blood, compared to people with a typical life span. Previous studies have found that people with type O blood have a lower risk of coronary heart disease and cancer, and have lower cholesterol levels than people with other blood types.

Another genetic variant in the CDKN2B gene seems to play a role in whether cells continue to divide, or stop dividing. Given that the stoppage of cell division, called senescence, is thought to contribute to aging, having a gene variation that reduces cell senescence could be a factor that contributes to successful aging, Kim said.

Kim suspects that there are still more genes linked with a longer life span.

"I hope our paper inspires other people to continue searching for" genes linked with longevity, Kim said.

The study was published yesterday (Dec. 17) in the journal PLOS Genetics.

Follow Rachael Rettner @RachaelRettner. FollowLive Science @livescience, Facebook& Google+. Original article on Live Science.

Originally posted here:
Living to 100: New Genes for Longevity Found | Live Science

In 2013, Google cofounder and CEO Larry Page announced the formation of a new Alphabet entity dedicated to solving the pesky puzzle of mortality. Since then, the billion-dollar longevity lab known as Calicoshort for California Life Companyhas been trying to tease apart the fundamental biology of aging in the hopes of one day defeating death. The hyper-secretive research venture has released few details about what it actually does inside its Silicon Valley lab, but there have been hints. One of the companys first hires was renowned geneticist Cynthia Kenyon, a UC San Francisco researcher who 20 years ago doubled the lifespan of a lab roundworm by flipping a single letter in its DNA.

Shortly after joining Calico, Kenyon recruited a UCSF bioinformatics postdoc named Graham Ruby. He didnt want to dig into worm genetics or study the companys colony of long-lived naked mole rats. He wanted to first ask a much broader question: how big a role do genes play, anyway, in determining how long someone lives? Other scientists had tried to ask that question before, with conflicting results. To clear things up would require getting much, much more data. So Calico went to the biggest family history database in the world: the consumer genetics and genealogy firm Ancestry.

In 2015, the companies inked a research partnership to investigate the human heredity of lifespan, with Ruby leading the charge to sift through Ancestrys vast forest of family trees. What he found by analyzing the pedigrees of more than 400 million people who lived and died in Europe and America going back to 1800 was that although longevity tends to run in families, your DNA has far less influence on how long you live than previously thought. The results, published Tuesday in the journal Genetics, is the first research to be made public from the collaboration, which ended quietly in July and whose terms remain confidential.

The true heritability of human longevity for that cohort is likely no more than seven percent, says Ruby. Previous estimates for how much genes explain variations in lifespan have ranged from around 15 to 30 percent. So what did Ruby uncover that previous studies had missed? Just how often amorous humans go against the old adage that opposites attract.

It turns out that through every generation, people are much more likely to select mates with similar lifespans than random chance would predict. The phenomenon, called assortative mating, could be based on genetics, or sociocultural traits, or both. For example, you might choose a partner who also has curly hair, and if the curly-haired trait winds up being somehow associated with long lifespans, this would inflate estimates of lifespan heritability passed on to your kids. Same thing for non-genetic traits like wealth, education, and access to good health care. People tend to choose partners in their same income bracket with the same terminal degree, both of which are associated with living longer, healthier lives.

The first hint that something other than genetics or a shared family environment might be at work came when Ruby tried looking at in-law relatives. His analysis started with a set of family trees comprising 400 million individuals. The data had been cleaned, de-identified, and stitched together by genealogists and computer scientists at Ancestry based on subscriber-generated public information. Using the basic laws of heredityeveryone inherits half their DNA from one parent and half from the other, repeated across generationsRubys team looked at how related two people were and how long they lived. They investigated parent-child pairs, sibling pairs, various cousins, and so on. Nothing much surprising popped out there.

See original here:
The Key to a Long Life Has Little to Do With Good Genes

Have you ever wondered how long you might live? New research suggests that an important indicator of your probable life span may be your genes. Scientists have identified unique genetic signatures strongly associated with a long and healthy life, findings that could help to further the understanding of how certain genes may offer protection from common age-related diseases like cancer, dementia and cardiovascular disease. And one day the data might lead to the development of genetic tests to predict whether a person can expect to live into old age as well as guide intervention efforts to prevent age-related illness.

The study, led by Paola Sebastiani, professor of biostatistics at Boston University (B.U.) School of Pubic Health, and Thomas Perls, professor of medicine and geriatrics at the B.U. School of Medicine, was published online July 1 in Science.

A person's life span is thought to be largely determined by the combined effects of genetics and environmental factors. Twin studies, however, suggest genetics only account for approximately 20 to 30 percent of an individual's chance of surviving to age 85.

Lifestyle choices, particularly diet, exercise and smoking habits, play an undisputed role in determining not only how long one will live, but also how well one ages. Studies show that Seventh-Day Adventists, whose church encourages behaviors that promote healthy aging, have a well-documented average life span of 88 years, approximately eight years longer than the average U.S. citizen. For the most part, Adventists exercise regularly, are vegetarian, and don't smoke or drink alcohol.

Nevertheless, a glance at your family tree may indicate whether you have a familial tendency toward longevity. Research suggests that exceptional longevity (EL)living one to three decades beyond the average U.S. life span of approximately 80 yearsruns strongly in families. "Thathas always made us believe that genetics is playing a very important role in this wonderful trait," Perls said Wednesday in a press conference.

Genetic factors can contribute to the degree of longevity in at least two important ways: An individual may inherit certain genetic variations that predispose him or her to disease that decreases longevity; other gene variants may confer disease resistance, thereby increasing it.

To better understand the genetic components of longevity, the researchers analyzed the DNA of more than 800 subjects between the ages of 95 to 119 and compared it with DNA from random controls. The genome-wide survey identified specific genetic variations, or SNPs (single-nucleotide polymorphisms), that were associated with the longevity group.

Next, the researchers developed a genetic model comprising 150 SNPs in order to compute the predisposition of an individual toward EL. Their model successfully predicted exceptional longevity in a different sample of centenarians (individuals that live to age 100) with 77 percent accuracy. This demonstrates that EL is strongly associated with complex combinations of genetic variants.

The researchers found that, based on subjects' genetic profiles, the centenarians could be further divided into 19 subgroups, some of which were associated with delayed onset of age-related diseases such as dementia, hypertension and cardiovascular disease. These signatures represent different genetic paths to age 100 and beyond, Sebastiani said in the press conference.

"Centenarians are indeed a model of aging well," Perls said. Previous work has shown that 90 percent of centenarians are disability-free at the age of 93. In industrialized nations approximately one out of every 6,000 people lives beyond the age of 100. Supercentenarians, or individuals that are older than 110, are even rareronly one in seven million fall into this category.

Surprisingly, the researchers found that approximately 15 percent of control subjects also had the genetic signature associated with longevity. This suggests that many more people have the genetic potential to survive into old age than previously thought. "We know a lot about the human genome, but we also know that there is a lot that remains to be discovered," Sebastiani said. "Genetics is fundamental in EL, but it's not the only thing. So there may be other factors like environment or other lifestyles that may help people live longer and healthier lives," he added.

Importantly, there was no difference in the presence of known disease-associated gene variants between the longevity and control groups. The researchers conclude that EL may result from an enrichment of longevity-associated gene variants that may counteract the effects of having a disease-associated gene.

"I think this is a step towards making sense out of a lot of datagenetic data, environmental data, epidemiological datato help us understand factors that contribute to long and healthy life," says Winifred Rossi, deputy director of the Division of Geriatrics and Clinical Gerontology at the National Institute on Aging, who wasn't involved in the study.

"We're starting to get to the point where it might be possible to use the information about these variants to predict someone's likelihood of achieving EL," says Matt Kaeberlein, professor of pathology at the University of Washington in Seattle, also not involved in the study. He added that the challenge was to next move beyond this correlative study to figure out how these gene variations may lead to functional changes that contribute to the molecular process of aging.

The authors caution that further study and replication of their results in different populations is needed to verify their model before it will be useful for individual genetic testsor before longevity "cocktails" are created.

"My hope has always been with the study that we would learn much more about how to get lots of people to live to older age in good health and markedly delay their disability and age of onset of diseases," Perls said. "I look at the complexity of this puzzle and feel very strongly that this will not lead to treatments that will get a lot of people to become centenarians, but rather will make a dent in the onset of age-related diseases like Alzheimer's, for example."

More:
Live Long and Proper: Genetic Factors Associated with ...

Adrenomyeloneuropathy Treatment

In a recent study published by QY Research, titled Global Adrenomyeloneuropathy Treatment MarketResearch Report, analysts offer an in-depth analysis of the global Adrenomyeloneuropathy Treatment market. The study analyzes the various aspects of the market by studying its historic and forecast data. The research report provides a Porters five force model, SWOT analysis, and PESTEL analysis of the Adrenomyeloneuropathy Treatment market. The different areas covered in the report are Adrenomyeloneuropathy Treatment market size, drivers and restraints, segment analysis, geographic outlook, major manufacturers in the market, competitive landscape, value/volume data, marketing strategies, and expert views

Major Key Player operating in this report are: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1654351/global-adrenomyeloneuropathy-treatment-market

Segmental Analysis

The report has classified the global Adrenomyeloneuropathy Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Adrenomyeloneuropathy Treatment manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Adrenomyeloneuropathy Treatment industry.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

End Users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adrenomyeloneuropathy Treatment market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Adrenomyeloneuropathy Treatment industry. Based on our recent survey, we have several different scenarios about the Adrenomyeloneuropathy Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Adrenomyeloneuropathy Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenomyeloneuropathy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenomyeloneuropathy Treatment market in terms of revenue. Players, stakeholders, and other participants in the global Adrenomyeloneuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each end users segment in terms of revenue and forecast by each therapy segment in terms of revenue for the period 2015-2026. Regional and Country-level Analysis The report offers an exhaustive geographical analysis of the global Adrenomyeloneuropathy Treatment market, covering important regions, viz, North America, Europe, China and Australia. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each end users segment in terms of revenue for the period 2015-2026. Competition Analysis In the competitive analysis section of the report, leading as well as prominent players of the global Adrenomyeloneuropathy Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenomyeloneuropathy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenomyeloneuropathy Treatment market. The following players are covered in this report:, Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment Breakdown Data by Therapy, Steroid Replacement Therapy, Stem Cell Transplant Adrenomyeloneuropathy Treatment Breakdown Data by End Users, Hospitals, Clinics, Ambulatory Surgical Centers, Others

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa, and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Adrenomyeloneuropathy Treatment market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. The keyword market in the South, America region is also expected to grow in the near future.

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Adrenomyeloneuropathy Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics Adrenomyeloneuropathy Treatment

Key questions answered in the report:

What is the growth potential of the Adrenomyeloneuropathy Treatment market?

Which product segment will grab a lions share?

Which regional market will emerge as a frontrunner in the coming years?

Which application segment will grow at a robust rate?

What are the growth opportunities that may emerge in the Adrenomyeloneuropathy Treatment industry in the years to come?

What are the key challenges that the global Adrenomyeloneuropathy Treatment market may face in the future?

Which are the leading companies in the global Adrenomyeloneuropathy Treatment market?

Which are the key trends positively impacting the market growth?

Which are the growth strategies considered by the players to sustain hold in the global Adrenomyeloneuropathy Treatment market

Reasons to buy this report:

QY Research report is designed in a method that assists clients to acquire a complete knowledge of the overall market scenario and the important sectors.

This report consists of a detailed overview of market dynamics and comprehensive research.

Explore further market opportunities and identify high potential categories based on detailed volume and value analysis

Detail information on competitive landscape, recent market trends and changing technologies that can be useful for the companies which are competing in this market

Gaining knowledge about competitive landscape based on detailed brand share analysis to plan an effective market positioning

Enquire Customization in the Report

https://www.qyresearch.com/customize-request/form/1654351/global-adrenomyeloneuropathy-treatment-market

Finally, the global Adrenomyeloneuropathy Treatment Market is a valuable source of guidance for individuals and companies. One of the major reasons behind providing market attractiveness index is to help the target audience and clients to identify the several market opportunities in the global Adrenomyeloneuropathy Treatment market. Moreover, for a better understanding of the market, QY Research has also presented a key to get information about various segments of the global Adrenomyeloneuropathy Treatment market.

Table of content

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Adrenomyeloneuropathy Treatment Revenue1.4 Market Analysis by Therapy1.4.1 Global Adrenomyeloneuropathy Treatment Market Size Growth Rate by Therapy: 2020 VS 20261.4.2 Steroid Replacement Therapy1.4.3 Stem Cell Transplant1.5 Market by End Users1.5.1 Global Adrenomyeloneuropathy Treatment Market Share by End Users: 2020 VS 20261.5.2 Hospitals1.5.3 Clinics1.5.4 Ambulatory Surgical Centers1.5.5 Others1.6 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.6.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry1.6.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Global Growth Trends by Regions2.1 Adrenomyeloneuropathy Treatment Market Perspective (2015-2026)2.2 Adrenomyeloneuropathy Treatment Growth Trends by Regions2.2.1 Adrenomyeloneuropathy Treatment Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Adrenomyeloneuropathy Treatment Historic Market Share by Regions (2015-2020)2.2.3 Adrenomyeloneuropathy Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Adrenomyeloneuropathy Treatment Market Growth Strategy2.3.6 Primary Interviews with Key Adrenomyeloneuropathy Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Adrenomyeloneuropathy Treatment Players by Market Size3.1.1 Global Top Adrenomyeloneuropathy Treatment Players by Revenue (2015-2020)3.1.2 Global Adrenomyeloneuropathy Treatment Revenue Market Share by Players (2015-2020)3.1.3 Global Adrenomyeloneuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio3.2.1 Global Adrenomyeloneuropathy Treatment Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Adrenomyeloneuropathy Treatment Revenue in 20193.3 Adrenomyeloneuropathy Treatment Key Players Head office and Area Served3.4 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service3.5 Date of Enter into Adrenomyeloneuropathy Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Therapy (2015-2026)4.1 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)4.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026) 5 Adrenomyeloneuropathy Treatment Breakdown Data by End Users (2015-2026)5.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020)5.2 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026) 6 North America6.1 North America Adrenomyeloneuropathy Treatment Market Size (2015-2020)6.2 Adrenomyeloneuropathy Treatment Key Players in North America (2019-2020)6.3 North America Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)6.4 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe7.1 Europe Adrenomyeloneuropathy Treatment Market Size (2015-2020)7.2 Adrenomyeloneuropathy Treatment Key Players in Europe (2019-2020)7.3 Europe Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)7.4 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China8.1 China Adrenomyeloneuropathy Treatment Market Size (2015-2020)8.2 Adrenomyeloneuropathy Treatment Key Players in China (2019-2020)8.3 China Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)8.4 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Australia9.1 Australia Adrenomyeloneuropathy Treatment Market Size (2015-2020)9.2 Adrenomyeloneuropathy Treatment Key Players in Australia (2019-2020)9.3 Australia Adrenomyeloneuropathy Treatment Market Size by Therapy (2015-2020)9.4 Australia Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10Key Players Profiles10.1 Ascend Biopharmaceuticals10.1.1 Ascend Biopharmaceuticals Company Details10.1.2 Ascend Biopharmaceuticals Business Overview and Its Total Revenue10.1.3 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Introduction10.1.4 Ascend Biopharmaceuticals Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020))10.1.5 Ascend Biopharmaceuticals Recent Development10.2 Novadip Biosciences10.2.1 Novadip Biosciences Company Details10.2.2 Novadip Biosciences Business Overview and Its Total Revenue10.2.3 Novadip Biosciences Adrenomyeloneuropathy Treatment Introduction10.2.4 Novadip Biosciences Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.2.5 Novadip Biosciences Recent Development10.3 Eureka Therapeutics10.3.1 Eureka Therapeutics Company Details10.3.2 Eureka Therapeutics Business Overview and Its Total Revenue10.3.3 Eureka Therapeutics Adrenomyeloneuropathy Treatment Introduction10.3.4 Eureka Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.3.5 Eureka Therapeutics Recent Development10.4 Human Longevity10.4.1 Human Longevity Company Details10.4.2 Human Longevity Business Overview and Its Total Revenue10.4.3 Human Longevity Adrenomyeloneuropathy Treatment Introduction10.4.4 Human Longevity Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.4.5 Human Longevity Recent Development10.5 Regeneus10.5.1 Regeneus Company Details10.5.2 Regeneus Business Overview and Its Total Revenue10.5.3 Regeneus Adrenomyeloneuropathy Treatment Introduction10.5.4 Regeneus Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.5.5 Regeneus Recent Development10.6 Allogene Therapeutics10.6.1 Allogene Therapeutics Company Details10.6.2 Allogene Therapeutics Business Overview and Its Total Revenue10.6.3 Allogene Therapeutics Adrenomyeloneuropathy Treatment Introduction10.6.4 Allogene Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.6.5 Allogene Therapeutics Recent Development10.7 BioRestorative Therapies10.7.1 BioRestorative Therapies Company Details10.7.2 BioRestorative Therapies Business Overview and Its Total Revenue10.7.3 BioRestorative Therapies Adrenomyeloneuropathy Treatment Introduction10.7.4 BioRestorative Therapies Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.7.5 BioRestorative Therapies Recent Development10.8 Immatics Biotechnologies10.8.1 Immatics Biotechnologies Company Details10.8.2 Immatics Biotechnologies Business Overview and Its Total Revenue10.8.3 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Introduction10.8.4 Immatics Biotechnologies Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.8.5 Immatics Biotechnologies Recent Development10.9 NewLink Genetics10.9.1 NewLink Genetics Company Details10.9.2 NewLink Genetics Business Overview and Its Total Revenue10.9.3 NewLink Genetics Adrenomyeloneuropathy Treatment Introduction10.9.4 NewLink Genetics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.9.5 NewLink Genetics Recent Development10.10 Cytori Therapeutics10.10.1 Cytori Therapeutics Company Details10.10.2 Cytori Therapeutics Business Overview and Its Total Revenue10.10.3 Cytori Therapeutics Adrenomyeloneuropathy Treatment Introduction10.10.4 Cytori Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.10.5 Cytori Therapeutics Recent Development10.11 Talaris Therapeutics10.11.1 Talaris Therapeutics Company Details10.11.2 Talaris Therapeutics Business Overview and Its Total Revenue10.11.3 Talaris Therapeutics Adrenomyeloneuropathy Treatment Introduction10.11.4 Talaris Therapeutics Revenue in Adrenomyeloneuropathy Treatment Business (2015-2020)10.11.5 Talaris Therapeutics Recent Development 11Analysts Viewpoints/Conclusions 12Appendix12.1 Research Methodology12.1.1 Methodology/Research Approach12.1.2 Data Source12.2 Disclaimer12.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from a huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Adrenomyeloneuropathy Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026|Novadip Biosciences, Eureka...

News can be fascinating or frightening. Researchers have managed to hack into evolution by accelerating the transformation of the apes brain into a human-like brain thanks to a gene that increases the number of neural stem cells. The experiment was stopped for ethical reasons, but it still raises many questions about this kind of manipulation.

There are 95% of similarities between humans and chimpanzees. The human genome is therefore very similar to that of certain animals.

What if, thanks to genetic manipulation, apes became as intelligent as humans and competed with them as they did on the Planet of the Apes? The subject has fascinated scientists for years, and a new experiment brings us a little closer to Pierre Boules book, adapted for the cinema in 1968. German and Japanese researchers claim to have hacked into the evolution of the brain by increasing the volume of the neocortex in marmoset embryos.

Seven million years separate the great apes from the first Homo sapiens. A slow development led to an increase in the brain size and changes in its structure, including an increase in the cerebral neocortex. The latter, the youngest part of the cerebral cortex during evolution, is about three times the size of our closest relative, the chimpanzee. It is at the center of cognitive functions such as logical thinking and language. One of the key questions for scientists is how the neocortex was able to become so large and give us our cognitive abilities.

In the study published in the journal Science, Wieland Huttner and his colleagues at the Max Planck Institute for Cell Biology and Molecular Genetics (MPI-CBG) in Dresden have investigated the ARHGAP11B gene. The ARHGAP11B gene is the result of a mutation in the ARHGAP11A gene that occurred approximately 1.5 million years ago along the evolutionary line that led to todays Neanderthals, Denisovans, and humans after the line of descent separated from that of the chimpanzee. This gene encodes a protein known for its ability to increase the production of neural stem cells.

Read Also: Genetics Have Less Effect on Longevity, Calico Study Shows

The mutation in the ARHGAP11B gene from a single C to a G gene letter results in the loss of 55 nucleotides in the formation of the corresponding messenger RNA. This leads to a change in the transcription of the proteins amino acids, explains Wieland Huttner. This mutation seems to have directly influenced human evolution, he adds. By 2015, Huttner had succeeded in increasing the production of brain stem cells in mice, but with a boosted version of the gene. This time, German researchers joined forces with the Central Institute for Experimental Animals (CIEA) in Kawasaki and Keio University in Tokyo, pioneers in the creation of transgenic monkeys, to conduct an experiment with the normal version of the human gene in marmoset fetuses.

A larger, brain with more folding

The gene was implanted into Mykot embryos three to five days after ovulation. They then allowed the embryos to live to 101 days, 50 days before the normal date of birth. This allowed them to see three important developments in the development of the monkey brain:

Read Also: How Your Smartphone Can Reduce Your Brain Power and Harm Your Health

From here to the creation of monkeys that are so intelligent and competitive to humans, many hurdles have to still be overcome. However, to avoid any controversy, the researchers have taken all ethical precautions. It is not a question of working on apes or chimpanzees that are too close to humans, or of completing the birth of genetically modified apes. Wieland Huttner also hints at criticism of the Chinese experiment. It would have been irresponsible to complete the birth of the marmosets because the behavioral changes caused by the alteration of the neocortex are not known, says Huttner. So for the moment, we will not know whether these marmosets could have played chess with us.

Human-specific ARHGAP11B increases size and folding of primate neocortex in the fetal marmoset

Here is the original post:
Planet of the Apes: by Enlarging the Brains of Apes Are Scientists Creating Worthy Opponents to Humans - Gilmore Health News

COLORADO SPRINGS, Colo. This fall will mark two years since PRCA bareback rider J.R. Vezain suffered a broken back after riding Frontier Rodeo Companys Brazos Bash, Sept. 22, 2018, at the Pasadena (Texas) Livestock Show & Rodeo.

The injury required surgery and left Vezain with mobility issues from the waist down.

In February, Vezain traveled to Panama City, Panama, for stem cell treatment, receiving intrinsic injections in his spinal column and intravenous injections in his arm for localized healing.

Everything went pretty smoothly, said Vezain, 28, in a PRCA press release. Ive noticed I have a little bit more control and consistent movement, but other than that its still just a slow process of healing.

Although the Melstone cowboy isnt walking yet, he continues to set goals to get there and said he is on the up.

I know God has a plan and his time is perfect, so I just keep trying to do something every day to get better and better myself, he said.

Vezain, a six-time qualifier for the National Finals Rodeo (2012-14, 2016-18), spent six months at a rehabilitation facility in Sandy, Utah, after the accident. Hes continued rehab exercises at his home gym, with his next goal being able to stand on his own.

My core is really strong, said Vezain, who previously resided in Cowley, Wyoming. Ive been working on balance, sitting on a balance ball and using discs. We have a walking machine where (with assistance) I walk and stretch. If I can stand, I can start to move my legs. I have enough control, like to crawl, and my hip flexor muscles are working. I have some leg movement, but Ive got to be able to stand first.

Vezain has also kept busy on the ranch, doing yard work, branding and gelding colts.

Ive also been busy doing leatherwork, I have a bunch of orders Im trying to catch up on, and just staying busy around the place, he said.

This year, Vezain began judging at bull riding events (not sanctioned by the PRCA).

As a rodeo cowboy, the last thing you ever think youre going to be is a rodeo judge, so that was something I had to get over, he said. But it keeps me connected and still involved in the sport. Its been fun being on the other side, really diving into rules and regulations, and knowing why a judge makes the calls they do. Its allowed me to get my mind off everything at the ranch and stay involved in rodeo.

Vezain said he keeps in touch periodically with his ProRodeo buddies. His brother-in-law Sage Newman of Melstone competes in saddle bronc riding.

The last rodeo I attended was in December (2019) to watch him compete, he said.

Vezain has done some motivational speaking at local high schools and churches. He also writes a monthly column for Rodeo News magazine.

Public speaking isnt really my forte, but every opportunity that has come up Ive been willing to share my story to hopefully provide some encouragement along the way, he said. I believe that every time Im asked to speak its for a reason and that somebody needs to hear the message.

Sharing his story also keeps Vezain motivated and grounded on achieving his goals.

My long-term goal would be to walk around and ride horses normally, he said. Ive always had dreams and aspirations to be able to train working cow horses. I want to be able to train horses again, play tackle football with my boy and work my ranch normally again.

On May 17, Vezains son, Ryatt, turned 1 year old.

Keeping up with him has also been a goal now that hes running amok.

Since the accident, Vezain said family and friends have helped in numerous ways, including assistance with remodeling his home and ranching needs.

Weve had a tremendous amount of help financially, physically, spiritually and emotionally from great people who are willing to reach out, he said. After the wreck, I put it all in Gods hands and said, Ill do my best to use the tools youve given me and the opportunity youve given me to spread your word. Ive always been willing to share my story and testimony to spark inspiration in others.

Read more:
Nearly 2 years removed from serious back injury, Melstone cowboy J.R. Vezain continuing to progress - 406mtsports.com

(June 2020) Stratagem Market Insights published the latest research report on Cancer Stem Cells (CSCs) Market 2027: Delivering key insights and providing a competitive advantage to clients through a detailed report. Cancer Stem Cells (CSCs) Market Size, Industry Share Value, Competitors Research, Industry Outlook as well Analysis covers various crucial factors like Regional Analysis, Cancer Stem Cells (CSCs) Type, Applications, etc.

The intelligence in Cancer Stem Cells (CSCs) Market report by Stratagem Market Insights includes investigations based on current situations, historical records, and future predictions. Conclude an accurate data of various aspects. It presents the 360 overview of the competitive landscape of the industries. Thus, helping the companies to understand the threats and challenges in front of the businesses.

To learn more about this report, request a sample copy*

The sample copy includes Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Get Sample Copy of Report:https://www.stratagemmarketinsights.com/sample/8303

The Key Manufacturers covered in this Report:-

Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech

*other Player can be added on demand)

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth.

In recent months, the majority of vendors are focused on developing strategies that will help them to remain agile during the global disruptions. This report is intended to give all details regarding the changing government policies. Government bodies of many countries are making strong decisions such as the introduction of new regulations. The latest study offers a detailed analysis of the impact of these regulations on the Cancer Stem Cells (CSCs) market during the upcoming years. The data incorporated in this report is crafted to help new entrants as well as well-established vendors who aim to lead the Cancer Stem Cells (CSCs) market.

The report covers the following insights and assessment that are helpful for all participants involved in the Cancer Stem Cells (CSCs) Market:

Global Cancer Stem Cells (CSCs) Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers a different scope to the market as each region has different government policies and other factors. The regions included in the report are North America, Europe, Asia Pacific, and the Middle East and Africa.

What insights does the Cancer Stem Cells (CSCs) market report provide to the readers?

Cancer Stem Cells (CSCs) Report Covers:

Executive Summary: Market Overview, Scope of Statistics of Cancer Stem Cells (CSCs) Market

Market Segmentation: Market by Type, Market By Application

Prominent Players:

Organization Information,

Product and Services,

Business Data,

Recent Development

Geographical segmentation: Regional Production, Regional Demand, Regional Trade

Price Overview: Cost by Manufacturers, Price by Application, Price by Type

At the end, Cancer Stem Cells (CSCs) Market reports deliver insight and expert analysis into key trends and behavior in the marketplace, in addition to an overview of the market data and key brands. Cancer Stem Cells (CSCs) Market reports provide all data with easily digestible information to guide every businessmans future innovation and move the business forward.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.stratagemmarketinsights.com/discount/8303

THANKS FOR SPENDING YOUR VALUABLE TIME ON THIS VALUABLE PIECE OF INFORMATION

Continue reading here:
Cancer Stem Cells (CSCs) Market Recent Industry Developments and Growth Strategies Adopted by Players - Cole of Duty

Studies conducted throughout its emergence and spread have documented the disturbing ways COVID-19 - the infectious disease caused by a newly discovered coronavirus - damages the body.

Coronavirus' are a family of respiratory infections so naturally the focus has mainly been on the damage it inflicts on the lungs.

However, a study of COVID-19 patients in Wuhan reported a range of neurological symptoms.

More than a third of coronavirus victims who were hospitalised in the Chinese city exhibited neurological symptoms, including dizziness, headache and seizures.

READ MORE:Coronavirus update: The current R number - are people in the UK still at risk of COVID-19?

Professor Hartung and colleagues made the discovery after adding low levels of SARS-COV-2, the virus responsible for Covid-19, to tiny neuronal balls known as mini-brains that are grown from human stem cells.

The researchers found the virus infected neurons in the mini-brains via the ACE2 human protein that is known to be an important entry point for SARS-COV-2.

The virus then multiplied within the neurons; within three days the number of copies had increased at least tenfold.

It is really critical to know that our most precious organ can be directly affected by the virus, said Prof Hartung, a toxicology expert at Johns Hopkins, adding it was still unclear how frequently this happened in COVID-19 patients.

According to the NHS, the main symptoms of coronavirus are:

"Most people with coronavirus have at least one of these symptoms," explains the health body.

UK health advice says to stay at home (self-isolate) if you have any of the main symptoms of coronavirus.

Anyone you live with, and anyone in your support bubble, must also self-isolate.

A support bubble is where someone who lives alone (or just with their children) can meet people from one other household.

There is currently no specific treatment for coronavirus (COVID-19), but you can often ease the symptoms at home until you recover.

However, If you have a high temperature, the NHS says it can help to:

"If you have a cough, it's best to avoid lying on your back. Lie on your side or sit upright instead," adds the health site.

Read more here:
Coronavirus symptoms: How COVID-19 can damage the brain - what to look for - Express

Global NK Cell Therapy and Stem Cell Therapy Market 2020-2025 Research Report is spread throughout 100+ pages and offers exclusive important statistics, informative data, key traits and competitive landscape details on this area of interest sector.

Global NK Cell Therapy and Stem Cell Therapy Market report offers the significant statistics to assist the corporations to cope up with the understanding gap due to the advancements within the enterprise and successfully utilize the possibilities that gift itself into the ever-converting market.

Attributes and market execution have investigated the use of quantitative and qualitative strategies to give a clear photograph of cutting-edge and future boom trends. A unique market analysis based totally on geographic locations is also provided in NK Cell Therapy and Stem Cell Therapy industry record. The international NK Cell Therapy and Stem Cell Therapy Market report offers the statistics diagrams, figures, and collateral that illustrates the country of the particular trade within the local and global scenario.

Download FREE Sample PDF (including full TOC, Tables and Figures) of NK Cell Therapy and Stem Cell Therapy Market @ https://www.eonmarketresearch.com/sample/72746

Top Manufacturers Listed in the NK Cell Therapy and Stem Cell Therapy Market Report are: Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen.

The report highlights the major area of NK Cell Therapy and Stem Cell Therapy Market:

1. The research analysts elaborate on the NK Cell Therapy and Stem Cell Therapy value chain and its distributor analysis in detail. This research study illustrates thorough information that improves the scope, application, and understanding of the NK Cell Therapy and Stem Cell Therapy market. The world NK Cell Therapy and Stem Cell Therapy Market report consists of an entire industry oveNK Cell Therapy and Stem Cell Therapyiew to provide consumers with a complete concept of the NK Cell Therapy and Stem Cell Therapy market situation and its trends.

2. The extensive view of the NK Cell Therapy and Stem Cell Therapy research is pursued by application, segmentation, and regional analysis of the market. This ensures that NK Cell Therapy and Stem Cell Therapy clients get good knowledge about each section. It also explains facts about the worldwide NK Cell Therapy and Stem Cell Therapy market and key pointers in terms of its growth and sales.

3. The report describes an in-depth analysis of the key NK Cell Therapy and Stem Cell Therapy industry players coupled with the profiles and their tendency towards the market. That analyzes NK Cell Therapy and Stem Cell Therapy Market price, cost, gross, revenue, specifications, product picture, company profile, and contact information.

4. The report comprehensively analyzes the Global NK Cell Therapy and Stem Cell Therapy market status, supply, sales, and production. The NK Cell Therapy and Stem Cell Therapy market shares of production and sales are evaluated along with the review of the production, capacity, sales, and revenue. Various aspects such as NK Cell Therapy and Stem Cell Therapy import or export, price, gross margin, consumption, and cost are also analyzed. On the whole, the report covers the NK Cell Therapy and Stem Cell Therapy market view and its growth probability for upcoming years.

5. The report also briefs all challenges and opportunities in the NK Cell Therapy and Stem Cell Therapy market. The study discusses NK Cell Therapy and Stem Cell Therapy market key events, new innovations, and top players strategies. The client gets wide knowledge and deep perceptive of NK Cell Therapy and Stem Cell Therapy restraints, distinct drivers, and factors impacting the industry. So that they can plan their growth map of the NK Cell Therapy and Stem Cell Therapy industry for the coming years.

Buy This Premium Report @https://www.eonmarketresearch.com/buy/72746

By Types:

NK Cell TherapyStem Cell Therapy

By Applications:

Hospital and clinicsRegenerative medicine centersDiagnostic centersResearch institutesOthers

Covering Region:

1. South America NK Cell Therapy and Stem Cell Therapy Market Covers Colombia, Brazil, and Argentina.2. North America NK Cell Therapy and Stem Cell Therapy Market Covers Canada, United States, and Mexico.3. Europe NK Cell Therapy and Stem Cell Therapy Market Covers UK, France, Italy, Germany, and Russia.4. The Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Covers UAE, Saudi Arabia, Egypt, Nigeria, and South Africa.5. Asia Pacific NK Cell Therapy and Stem Cell Therapy Market Covers Korea, Japan, China, Southeast Asia, and India.

Do Inquiry Before Purchasing Report Here and Ask For Discount @ https://www.eonmarketresearch.com/enquiry/72746

About Us:

Eon Market Research is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: [emailprotected]

Go here to read the rest:
Global NK Cell Therapy and Stem Cell Therapy Market Top Key Players, Regions, Type and Application Outlook Upto 2020 to 2025 - 3rd Watch News

Hematopoietic Stem Cells Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cells Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cells Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cells Transplantation (HSCT) sales, revenue and market share for each player covered in this report.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

Synopsis of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

Based onProduct Type, Hematopoietic Stem Cells Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

Autologous Transplant Allogenic Transplant

Based onend users/applications, Hematopoietic Stem Cells Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

Hematopoietic Stem Cells Transplantation (HSCT) Market: Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

The Hematopoietic Stem Cells Transplantation (HSCT) Market Report Can Answer The Following Questions:

What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cells Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cells Transplantation (HSCT)?

Who are the key manufacturers of Hematopoietic Stem Cells Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?

Economic impact on Hematopoietic Stem Cells Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cells Transplantation (HSCT) industry.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cells Transplantation (HSCT)?

What will the Hematopoietic Stem Cells Transplantation (HSCT) Market Size and The Growth Rate be in 2026?

What are the key market trends impacting the growth of the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) Market Challenges to market growth?

What are the types and applications of Hematopoietic Stem Cells Transplantation (HSCT)? What is the market share of each type and application?

What are the key factors driving the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cells Transplantation (HSCT) market?

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Go here to see the original:
Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix...

Global Stem Cell Assay Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the global Stem Cell Assay Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Stem Cell Assay Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a Global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Stem Cell Assay market between 2020 and 2027. In terms of value, the Stem Cell Assay industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1632

The key players profiled in this report include: Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Stem Cell Assay

o The micro-level analysis is conducted based on its product types, end-user applications, and geographie

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Stem Cell Assay market

Table of Contents

Report Overview: It includes the Stem Cell Assay market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Stem Cell Assay market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Stem Cell Assay market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Stem Cell Assay market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1632

The research study can answer the following Key questions:

Major Highlights of TOC:

Chapter One: Global Stem Cell Assay Market Industry Overview

1.1 Stem Cell Assay Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Stem Cell Assay Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Stem Cell Assay Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Stem Cell Assay Market Size by Demand

2.3 Global Stem Cell Assay Market Forecast by Demand

Chapter Three: Global Stem Cell Assay Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Stem Cell Assay Market Size by Type

3.3 Stem Cell Assay Market Forecast by Type

Chapter Four: Major Region of Stem Cell Assay Market

4.1 Global Stem Cell Assay Sales

4.2 Global Stem Cell Assay Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1632

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Originally posted here:
Stem Cell Assay Market Future Trends and Forecast to 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad...

New Jersey, United States,- The latest research study on Stem Cell Therapy Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Stem Cell Therapy market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Download Sample Copy of Stem Cell Therapy Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=APS&utm_medium=007

The research report on the Stem Cell Therapy market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Stem Cell Therapy market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Stem Cell Therapy market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Stem Cell Therapy market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Stem Cell Therapy Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=APS&utm_medium=007

As per the regional scope of the Stem Cell Therapy market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=APS&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Influenza Diagnostics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Biomarkers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

3D Bioprinting Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See original here:
Stem Cell Therapy Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News

New Jersey, United States,- The latest research study on Stem Cell Banking Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Stem Cell Banking market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Stem Cell Banking Market was valued at USD 1.47 billion in 2016 and is projected to reach USD 7.52billion by 2025, growing at a CAGR of 19.89% from 2017 to 2025.

Download Sample Copy of Stem Cell Banking Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=23773&utm_source=APS&utm_medium=007

The research report on the Stem Cell Banking market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Stem Cell Banking market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Stem Cell Banking market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Stem Cell Banking market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Stem Cell Banking Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23773&utm_source=APS&utm_medium=007

As per the regional scope of the Stem Cell Banking market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Banking-Market/?utm_source=APS&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Pyrogen Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Banking Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Expansion Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wearable Skin Patch Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Fetal Monitoring Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more here:
Stem Cell Banking Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News

Dublin, June 25, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2019-2028" report has been added to ResearchAndMarkets.com's offering.

The global CRISPR market is estimated to expand at a CAGR of 23.95% over the forecasting period 2019-2028.

The increasing lifestyle-oriented diseases, the rising prevalence of genetic diseases and the growing application of drugs are the primary factors driving the growth of the CRISPR market. In addition, the increasing geriatric population and the rising incidence of genetic ailments are also likely to lead to an increase in demand for global CRISPR technology. However, ethical issues associated with the technology and the changing regulatory environment is restraining the market. The market is also challenged by the availability of alternate technologies and the lack of awareness regarding CRISPR. But, the advancements in the gene-based therapy application and the increased demand for CRISPR will create market opportunities.

The global market report covers the countries from North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Asia-Pacific is likely to be the fastest-growing for the CRISPR market in the world. With the rapidly advancing technological developments and the wide range of applications of CRISPR technology in countries like India and China, regional growth is expected in the next few years. China has already started various gene-editing research work focusing on the CRISPR technology market.

The major companies in the CRISPR market are Horizon Discovery Ltd, Integrated DNA Technologies Inc, Caribou Biosciences Inc, Precision Biosciences, Lonza, Addgene, Origene Technologies Inc, Genedata AG, Intellia Therapeutics Inc, Cellectis, Applied StemCell, Transposagen Bio (Hera BioLabs), GeneCopoeia Inc, Sigma-Aldrich (Merck KGaA), DiaCarta, Editas Medicine, New England Biolabs, Sangamo Therapeutics, GenScript, Thermo Fisher Scientific Inc and CRISPR Therapeutics.

Applied StemCell is a company that aims at stem cell and gene-editing in the field of biotechnology and the biomedical sector. It offers its services in different fields for drug discovery, basic research study, bioproduction and bioprocessing. The company is working on various projects that will combine TARGATT and CRISPR/Cas9 technology. The company is headquartered in California, the US, and has a global presence with business operations in various countries, including Australia, Germany, Belgium, Canada, Denmark, Hong Kong, India, Japan, Malaysia, Thailand and Turkey.

Key Topics Covered:

1. Global CRISPR Market - Summary

2. Industry Outlook2.1. Market Definition2.2. Porter's Five Forces Model2.2.1. Threat of New Entrants2.2.2. Threat of Substitute Products2.2.3. Bargaining Power of Buyers2.2.4. Bargaining Power of Suppliers2.2.5. Competitive Rivalry2.3. Regulatory Outlook2.4. Value Chain Outlook2.5. Supply Chain Outlook2.6. Timeline of Global CRISPR Market2.7. Parent Market Outlook2.8. Key Insight2.9. Market Attractiveness Index2.10. Market Drivers2.10.1. Growing Lifestyle-Oriented Diseases2.10.2. Surging Prevalence of Genetic Diseases2.10.3. Increasing Application of Drugs2.10.4. Rising Aging Population2.10.5. Incidence of Genetic Ailments2.11. Market Restraints2.11.1. Ethical and Social Issues Associated With CRISPR Technology2.11.2. Changing Regulatory Environment2.12. Market Opportunities2.12.1. Increased Demand for CRISPR 2.12.2. Advancements in the Applications of Gene-Based Therapy2.13. Market Challenges2.13.1. Alternative Technologies2.13.2. Lack of Awareness Regarding the Technology

3. CRISPR Market Outlook - By Product3.1. Plasmids3.2. Vectors3.3. Proteins3.3.1. Cas 93.3.2. Cpf13.3.3. Other Proteins3.4. Design Tools3.5. Grna3.6. Control Kits3.7. Library3.8. Other Products

4. CRISPR Market Outlook - By Application4.1. Genome Editing/Genetic Engineering4.1.1. Genetically Modified Organisms4.1.2. Agricultural Biotechnology4.1.3. Other Genome Editing/Genetic Engineering4.2. Grna Database/Gene Library4.3. CRISPR Plasmid4.4. Human Stem Cells4.5. Cell Line Engineering

5. CRISPR Market Outlook - By End-User5.1. Therapeutics and Drug Discovery5.2. Biological Research5.3. Agricultural Biotech5.4. Industrial Biotech

6. CRISPR Market - Regional Outlook6.1. North America6.1.1. Market By Product6.1.2. Market By Application6.1.3. Market By End-User6.1.4. Country Outlook6.1.4.1. the United States6.1.4.2. Canada6.2. Europe6.2.1. Market By Product6.2.2. Market By Application6.2.3. Market By End-User6.2.4. Country Outlook6.2.4.1. the United Kingdom6.2.4.2. France6.2.4.3. Germany6.2.4.4. Spain6.2.4.5. Italy6.2.4.6. Russia6.2.4.7. Rest of Europe6.3. Asia-Pacific6.3.1. Market By Product6.3.2. Market By Application6.3.3. Market By End-User6.3.4. Country Outlook6.3.4.1. India6.3.4.2. China6.3.4.3. Japan6.3.4.4. South Korea6.3.4.5. Australia & New Zealand6.3.4.6. Asean Countries6.3.4.7. Rest of Asia-Pacific6.4. Latin America6.4.1. Market By Product6.4.2. Market By Application6.4.3. Market By End-User6.4.4. Country Outlook6.4.4.1. Brazil6.4.4.2. Mexico6.4.4.3. Rest of Latin America6.5. Middle East and Africa6.5.1. Market By Product6.5.2. Market By Application6.5.3. Market By End-User6.5.4. Country Outlook6.5.4.1. Saudi Arabia6.5.4.2. Turkey6.5.4.3. United Arab Emirates6.5.4.4. South Africa6.5.4.5. Rest of Middle East & Africa

7. Company Profile7.1. Addgene7.2. Applied Stemcell 7.3. Caribou Biosciences Inc7.4. Cellectis7.5. CRISPR Therapeutics 7.6. Diacarta 7.7. Editas Medicine7.8. Genecopoeia Inc7.9. Genedata Ag7.10. Genscript7.11. Horizon Discovery Ltd7.12. Integrated Dna Technologies Inc7.13. Intellia Therapeutics Inc7.14. Lonza 7.15. New England Biolabs 7.16. Origene Technologies Inc7.17. Precision Biosciences7.18. Sangamo Therapeutics7.19. Sigma-Aldrich (Merck Kgaa)7.20. Thermo Fisher Scientific Inc7.21. Transposagen Bio (Hera Biolabs)

8. Research Methodology & Scope8.1. Research Scope & Deliverables8.1.1. Objectives of Study8.1.2. Scope of Study8.2. Sources of Data8.2.1. Primary Data Sources8.2.2. Secondary Data Sources8.3. Research Methodology8.3.1. Evaluation of Proposed Market8.3.2. Identification of Data Sources8.3.3. Assessment of Market Determinants8.3.4. Data Collection8.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/u9j8i0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Insights on the CRISPR Global Industry to 2028 - Featuring Applied Stemcell, Caribou Biosciences & Cellectis Among Others - GlobeNewswire

The worldwide pandemic CoVid-19 has given a new meaning to the term normal. Staying indoors, taking extreme precautions while going out and reinventing the way to do business is now the new normal. It is acutely affecting the academic pursuits of millions of students everywhere with 1.53 billion students out of school and colleges, impacting 87.6% of the worlds total enrolled students.

For online registrations in UG/PG programmes, Click Here

But, at Sharda, the pandemic has not stopped its students passion to continue learning. Regular online classes and best IT practices have ensured that knowledge sharing continues unabated. Thats why Sharda University has become one of Indias first few universities to receive QS I-Gauge E-LEAD Certificate for excellence in online education. Sharda University is proud to be rated by the very prestigious NIRF (The National Institutional Ranking Framework) and accredited by NAAC (National assessment and Accreditation Council). It was very recently awarded with Gold standard by the globally renowned QS I-Gauge 2020.

For online registrations in UG/PG programmes, Click Here

While the situation arising out of CoVid-19 is truly challenging, Sharda University has once again risen to the occasion by giving a new dimension to its prestigious admission test by making it Artificial Intelligence-enabled. A remote-proctored online solution has been made available for students taking the test. The move from conventional test to an online examination will enable candidates to take the test from the convenience of their home without worrying about their health and safety in the wake of CoVid-19 pandemic.

Like centre-based testing, SUAT will require candidates to complete a virtual self-check-in process, which includes enhanced identification, authentication and, after successful validation, the candidate will be approved to take the test. The remote proctoring tool allows students to conveniently and easily take the SUAT exam while being monitored online using a webcam and the respondents computer screen.

Sharda Universitys sprawling 63 acre campus offers world-class learning facilities and has taken all measures for safety of students from Covid-19 through regular sanitization. The on-campus 900+ beds Sharda Hospital also has a dedicated testing facility for Covid-19 and has so far successfully treated more than 100 Corona patients.

Sharda University also offers choice of free one semester study option in select programmes at its Uzbekistan campus. Being the only global university in India with students from 85+ countries, and academic partnerships with 250+ universities across the world the USA, the UK, Italy, Canada, Russia, Slovania, et al, Sharda University offers a truly international learning environment. Thats why it says, The World is Here, Where are You?

For online registrations in UG/PG programmes, Click Here

Have a look at the campus virtual tour: Click Here

Disclaimer: Content Produced by SHARDA UNIVERSITY

See the rest here:
SUAT - Gateway to India's truly global university is now fully online - Times of India

The Human Primary Cells Marketprovides qualitative and quantitative research to provide a complete and comprehensive analysis of the Competition, Covid-19 Impact on Industry Insights for Human Primary Cells Market. It is a detailed report that focuses on primary and secondary factors, market share, top divisions, and regional analysis. It is a series of empirical analysis based on past data, current and future estimates, and predicted Human Primary Cells Market market developments. Research on various sectors including high-leading players opportunities, volume, growth, technology, demand, and the trend has been reviewed.

Download a Sample Copy of Report athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2722066

The Global Human Primary Cells Market Report research is also compiled on the basis of the current and emerging technologies, opportunities, and developments, according to the latest report from ReportsnReports Research. Human Primary Cells Market predicts that overall growth in demand over the forecast period (20192024) will remain moderate.

The Human Primary Cells market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Human Primary Cells market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Human Primary Cells market.

Major players in the global Human Primary Cells market include:Zen-BioCell BiologicsCurelinePelobiotechThermo Fisher ScientificLonzaStemcell TechnologiesPromoCell GmbHSigma-Aldrich

On the basis of types, the Human Primary Cells market is primarily split into:Epithelial CellsFibroblastsHematopoieticLiver CellsMesenchymal Stem CellsMuscle CellsPericytes

On the basis of applications, the market covers:Medical ResearchClinical ResearchOther

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:United StatesEurope (Germany, UK, France, Italy, Spain, Russia, Poland)ChinaJapanIndiaSoutheast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)Central and South America (Brazil, Mexico, Colombia)Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)Other Regions

Chapter 1 provides an overview of Human Primary Cells market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Human Primary Cells market by type, application, and region are also presented in this chapter.Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.Chapter 3 provides a full-scale analysis of major players in Human Primary Cells industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.Chapter 4 gives a worldwide view of Human Primary Cells market. It includes production, market share revenue, price, and the growth rate by type.Chapter 5 focuses on the application of Human Primary Cells, by analyzing the consumption and its growth rate of each application.Chapter 6 is about production, consumption, export, and import of Human Primary Cells in each region.Chapter 7 pays attention to the production, revenue, price and gross margin of Human Primary Cells in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.Chapter 9 introduces the industrial chain of Human Primary Cells. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.Chapter 10 provides clear insights into market dynamics.Chapter 11 prospects the whole Human Primary Cells market, including the global production and revenue forecast, regional forecast. It also foresees the Human Primary Cells market by type and application.Chapter 12 concludes the research findings and refines all the highlights of the study.Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:Historical Years: 2014-2018Base Year: 2019Estimated Year: 2019Forecast Period: 2019-2026

Get a 20% Discount on this Report athttps://www.reportsnreports.com/contacts/discount.aspx?name=2722066

The Goal of Human Primary Cells Market Report is to provide a complete market evaluation which includes insightful observations, information, actual data, market data verified by the industry, and forecasts with a proper set of hypotheses and methodologies. The study also analyzes global companies, including patterns in growth, opportunities for industry, investment strategies, and conclusions from experts. The study focuses on globally performing key players to clarify, identify, and analyze the multiple aspects of the demand for Human Primary Cells Market.

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.We provide 24/7 online and offline support to our customers.

E-mail: [emailprotected]

Phone: +1 888 391 5441

More here:
Human Primary Cells Market Global ? How the Market has witnessed Substantial Growth in recent years? - 3rd Watch News